Premium
Autonomic nervous system Clinical neurophysiology Critical care
Author(s) -
H. Acar,
K. Durak,
F. Aysal,
S. Karamursel,
I. Kara,
A. Nurten,
M. Ozturk,
S. Baybas,
M. Reichel,
W. Mayr,
E. Unger,
M. Frey
Publication year - 2002
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/j.1468-1331.2002.tb00043.x
Subject(s) - medicine , clinical neurophysiology , citation , neurophysiology , autonomic nervous system , computer science , world wide web , psychiatry , electroencephalography , heart rate , blood pressure
rallel with intrathecal treatment and 2 pts (10%) systemic hormonal treatment. The whole brain radiotherapy was performed additionally in fourteen (70%) pts. Results The mean age at the time of diagnosis of MC was 45 years (range 29-70) and the median Karnofsky status was 50% (range 40-80%). The clinical symptoms at the time of diagnosis were headache (85%), nausea/vomiting (40%), confusion (30%), cerebellar signs (25%), paresis (25%) and pain in the thoraco-lumbar region (10%). Cancer cells in cerebrospinal fluid were detected in 100% of cases. Cerebrospinal fluid protein level was elevated in 70% of cases. The mean of intrathecal treatment cycles was 6, (range 0-15 cycles). The response was defined as clinical and laboratory improvement and was achieved in fourteen pts (70%). The median duration of survival was 112 days. Conclusion Our observation suggests, how important prognostics factors in MC are: systemic chemotherapy, Karnofsky status at time the diagnosis of MC and the clinical response (reduction of headache and other symptoms) after the first 2-3 cycles of intrathecal infusion of methotrexate.